December 31, 2014 — Reva Medical initiated patient enrollment with its Fantom...
Stents Bioresorbable
This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction.
December 10, 2014 — In the first successful United States trial of a bioabsorbable polymer stent, the Boston...
Nov. 14, 2014 — Micell Technologies Inc. announced commercialization plans for its MiStent...
By Dave Fornell, editor of DAIC Magazine
...October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb...
October 7,2014 — Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in...
By Dave Fornell, editor of DAIC Magazine
The key take away messages from the 26th annual Transcatheter...
September 24, 2014 — A new study that compares the use of an everolimus-eluting...
September 24, 2014 — Abbott announced positive one-year clinical results from ABSORB II, the world's first...
DAIC Editor, Dave Fornell, interviews Jim Hermiller, M.D., FACC, director of interventional cardiology, St. Vincent...
July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and...
May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting...
April 16, 2014 — Abbott announced it has completed enrollment of three...